2.27
0.04 (1.79%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Neumora Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -1.5 |
| 平均 | -0.75 |
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 27.57% |
| 机构持股比例 | 60.62% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 30 Sep 2025 | 3,309,123 |
| Lunate Capital Ltd | 30 Sep 2025 | 2,124,143 |
| Lunate Holding Rsc Ltd | 31 Dec 2024 | 2,124,143 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 14.00 (Guggenheim, 516.74%) | 购买 |
| 中 | 7.50 (230.40%) | |
| 低 | 3.00 (Stifel, 32.16%) | 保留 |
| 平均值 | 8.00 (252.42%) | |
| 总计 | 3 购买, 1 保留 | |
| 平均价格@调整类型 | 2.57 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| RBC Capital | 01 Dec 2025 | 7.00 (208.37%) | 购买 | 2.42 |
| Stifel | 17 Nov 2025 | 3.00 (32.16%) | 保留 | 2.59 |
| Needham | 28 Oct 2025 | 8.00 (252.42%) | 购买 | 2.59 |
| Guggenheim | 27 Oct 2025 | 14.00 (516.74%) | 购买 | 2.69 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合